You are here

Merck

Merck's Deal With Seagen May Have Fallen Through. Now What?

Merck's Deal With Seagen May Have Fallen Through. Now What?

Motley Fool

Flag link:

Merck and Seagen can't agree on a price for their rumored merger

Merck and Seagen can't agree on a price for their rumored merger

Fierce Pharma

Flag link:

Merck backs radiopharmaceutical startup Aktis, joining other high-profile backers

Merck backs radiopharmaceutical startup Aktis, joining other high-profile backers

BioPharma Dive

radiopharmaceuticals

Bristol Myers Squibb

Flag link:

Merck, seeking XI factor in race with Bayer, gets FDA fast-track tag for anticoagulant

Merck, seeking XI factor in race with Bayer, gets FDA fast-track tag for anticoagulant

Fierce Biotech

end-stage renal disease

Flag link:

Merck Makes Another Big R&D Investment with $3.5B Orna Deal

Merck Makes Another Big R&D Investment with $3.5B Orna Deal

BioSpace

Orna Therapeutics

infectious disease

Flag link:

With Pfizer, AZ and Merck leading the way, Big Pharma weathered the economic storm in Q2

With Pfizer, AZ and Merck leading the way, Big Pharma weathered the economic storm in Q2

Fierce Pharma

Flag link:

Seagen's (SGEN) Cancer Drugs Aid Growth, Stiff Rivalry a Woe

Seagen's (SGEN) Cancer Drugs Aid Growth, Stiff Rivalry a Woe

Yahoo/Zacks.com

Flag link:

FDA says found possible carcinogen in certain samples of Merck's Januvia

FDA says found possible carcinogen in certain samples of Merck's Januvia

Yahoo/Reuters

Flag link:

Merck is back in Alzheimer's saddle with $1B+ Cerevance pact, years after dropping the BACE

Merck is back in Alzheimer's saddle with $1B+ Cerevance pact, years after dropping the BACE

Fierce Biotech

Alzheimer's disease

Flag link:

Merck plans to count coughs and months until gefapixant is back in FDA hands

Merck plans to count coughs and months until gefapixant is back in FDA hands

Fierce Biotech

Flag link:

Merck's Keytruda, on a losing streak, fails in once FDA-rejected liver cancer use and prostate cancer—again

Merck's Keytruda, on a losing streak, fails in once FDA-rejected liver cancer use and prostate cancer—again

Fierce Pharma

Flag link:

Racing Merck and Pfizer, Roche readies to file subcutaneous Tecentriq after posting phase 3 data

Racing Merck and Pfizer, Roche readies to file subcutaneous Tecentriq after posting phase 3 data

Fierce Pharma

clinical trials

checkpoint inhibitors

Flag link:

Merck picks up another ADC agreement

Merck picks up another ADC agreement

Biopharma Reporter

antibody-drug conjugate

Sichuan Kelun Pharmaceutical

Flag link:

Drugmakers leap back into fading heart drug market

Drugmakers leap back into fading heart drug market

Beckers Hospital Review

Bristol Myers Squibb

Alnylam Pharmaceuticals

Flag link:

Merck Dives As Drug-Pricing Bills Undercut Second-Quarter Profit

Merck Dives As Drug-Pricing Bills Undercut Second-Quarter Profit

Investors Business Daily

Flag link:

Merck dodged billions in US taxes in offshoring Keytruda profits, Senate Democrats contend

Merck dodged billions in US taxes in offshoring Keytruda profits, Senate Democrats contend

Fierce Pharma

Flag link:

Senate Finance chair calls on Merck and Abbott to comply with his investigation into their offshore tax schemes

Senate Finance chair calls on Merck and Abbott to comply with his investigation into their offshore tax schemes

Endpoints

Flag link:

Merck's ADC hunt continues with second deal for China biotech Kelun

Merck's ADC hunt continues with second deal for China biotech Kelun

Endpoints

antibody-drug conjugate

Flag link:

Seagen, Astellas claim positive results in study key to cancer drug's success

Seagen, Astellas claim positive results in study key to cancer drug's success

BioPharma Dive

clinical trials

Flag link:

Merck’s Keytruda fails head and neck cancer trial

Merck’s Keytruda fails head and neck cancer trial

CNBC

head and neck cancer

clinical trials

Flag link:

Pages